<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662568</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DGLS4-18-001</org_study_id>
    <nct_id>NCT03662568</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects</brief_title>
  <official_title>A Open-label, Single Center Drug Interaction Study of Morphothiadine Mesilate/Ritonavir , Entecavir and Tenofovir Disoproxil Fumarate in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics
      (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or
      Tenofovir Disoproxil Fumarate in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study with each part is an open-label, crossover study in healthy adult
      subjects.

      Total 56 subjects will be enrolled into the study and divided into 2 part (Part A and Part
      B), 28 subjects in each part. Part A is to evaluate the drug-interaction between GLS4/RTV and
      ETV, Part B is to evaluate the drug-interaction between GLS4/RTV and TDF. With each part, the
      subject will be split into two groups and receive study drug per the defined treatment
      periods of Day 1, Day 11-20 and Day 21.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Maximum plasma concentration of study drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Area under the plasma concentration-time curve of study drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Time to maximum concentration of study drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Terminal half-life of study drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to day 23</time_frame>
    <description>To assess the safety and tolerability after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Apparent clearance of study drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Apparent volume of distribution of study drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Day 1-2 and Day 21-23</time_frame>
    <description>Minimum plasma concentration of study drugs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part A:Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A:Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS4</intervention_name>
    <description>Administered GLS4 120 mg orally three times daily in fed state</description>
    <arm_group_label>Part A:Group A</arm_group_label>
    <arm_group_label>Part A:Group B</arm_group_label>
    <arm_group_label>Part B:Group C</arm_group_label>
    <arm_group_label>Part B:Group D</arm_group_label>
    <other_name>Morphothiadine Mesilate Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>Administered RTV 100 mg orally three times daily in fed state</description>
    <arm_group_label>Part A:Group A</arm_group_label>
    <arm_group_label>Part A:Group B</arm_group_label>
    <arm_group_label>Part B:Group C</arm_group_label>
    <arm_group_label>Part B:Group D</arm_group_label>
    <other_name>Ritonavir tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETV</intervention_name>
    <description>Administered orally ETV 0.5 mg once daily in fasted state</description>
    <arm_group_label>Part A:Group A</arm_group_label>
    <arm_group_label>Part A:Group B</arm_group_label>
    <other_name>Entecavir table</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>Administered TDF 300 mg orally once daily in fasted state</description>
    <arm_group_label>Part B:Group C</arm_group_label>
    <arm_group_label>Part B:Group D</arm_group_label>
    <other_name>Tenofovir Disoproxil Fumarate table</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the informed consent form before the trial and fully understand the contents of
             the trial, the process and possible adverse reactions

          -  Be able to complete the study according to the trail protocol

          -  Subjects (including partners) have no pregnancy plan within 1 year after the last dose
             of study drug and voluntarily take effective contraceptive measures

          -  Male subjects and must be 18 to 45 years of age inclusive

          -  Body weight ≥ 50 kg and body mass index（BMI）between 18 and 28 kg / m2, inclusive

          -  Physical examination and vital signs without clinically significant abnormalities.

        Exclusion Criteria:

          -  Use of &gt;5 cigarettes per day during the past 3 months

          -  Known history of allergy to study drugs，or allergies constitution ( multiple drug and
             food allergies)

          -  History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25
             mL of spirits or 100 mL of wine)

          -  Donation or loss of blood over 450 mL within 3 months prior to screening

          -  12-lead ECG with clinically significant

          -  Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis

          -  Subjects deemed unsuitable by the investigator for any other reason.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

